

THERAPEUTIC AREA	PRODUCT	INDICATION	SAMPLES	TECHNICAL PACKAGE	VALIDATION BATCH	DMF
Antiasthmatics, COPD and respiratory diseases	Olodaterol^P	COPD	√	√	√	Q3 2023
	Indacaterol acetate	Asthma	Q3 2023	Q4 2023	Q1 2024	Q3 2024
Antiparkinson	Benserazide	Parkinson's disease	√	√	pending	pending
Other disorders	Tafamidis meglumine	Transthyretin amyloidosis	√	√	√	Q3 2024
	Lasmiditan succinate	Migraine	Q2 2023	Q2 2023	Q4 2023	Q4 2024
	Solriamfetol	Narcolepsy	Q3 2023	Q4 2023	Q1 2024	Q3 2024
	Prasugrel HCl	Prophylaxis & therapy of thrombosis	Q3 2023	Q4 2023	Q4 2023	Q2 2024
	Mavacamten	Cardiomyopathy	Q3 2023	Q1 2024	Q2 2024	Q1 2025

CEP = Products with Certificate of Suitability

P = Patent applications/granted patents owned by INKE S.A.

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular, these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.